Christopher Vandyck, MD
Psychiatry · New Haven, CTNPI 1821088188
Payments from drug & device makers
Across 491 payments — averaging $42,267 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7.2M
- Eisai Inc.$7.1M
- Eli Lilly$3M
- Novartis$1.8M
- UCB SA$1.3M
- Merck$213K
- plus $130K from 6 others
Across 2 payments — averaging $465.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$930
What the payments were for
- Consulting fees$57,46082%
- Travel & lodging$11,19816%
- Food & beverage$1,6662%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 20 | $7,173,582 |
| Eisai Inc. | 392 | $7,071,602 |
| Eli Lilly | 20 | $3,005,484 |
| Novartis | 7 | $1,830,946 |
| UCB SA | 8 | $1,328,530 |
| Merck | 5 | $212,982 |
| Genentech, Inc. | 15 | $86,772 |
| F. Hoffmann-la Roche AG | 9 | $19,106 |
| AbbVie | 5 | $9,092 |
| Biohaven Pharmaceuticals, Inc. | 2 | $6,928 |
| E.r. Squibb & Sons, L.L.C. | 6 | $5,537 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $2,400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$20,811
- Non-Covered Product$15,406
- NONE$3,218
How this compares
$20,752,962 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 50 | $1,047 |
| Donepezil Hcl | 48 | $910 |
| Olanzapine | 20 | $275 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New Haven
- Vladimir CoricNew Haven$133.7M
- Adam MeccaNew Haven$5.1M
- Gerard SanacoraNew Haven$1.3M
- Ryan O'DellNew Haven$1.1M
- Roger JouNew Haven$910K
- Rajiv RadhakrishnanNew Haven$539K
- Sarah FinebergNew Haven$135K
- Robert BermanNew Haven$126K
- Christopher PittengerNew Haven$88K
- Paula ZimbreanNew Haven$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.